Sethera Therapeutics is pioneering advancements in peptide-based drug development through its innovative enzymatic cross-linking technology. This platform facilitates the synthesis of highly stable, polymacrocyclic peptides that are engineered to engage multiple biological targets simultaneously. By leveraging natural enzymatic processes, Sethera creates complex peptide structures that retain their stability and functionality in physiological conditions, which is crucial for developing effective treatments for challenging diseases such as cancer. The technology allows for high throughput screening at biological pH in aqueous solutions, enhancing the stability and efficacy of peptide therapeutics and enabling the targeting of heterogeneous biological systems.

The company’s approach focuses on generating unique peptide architectures that can modulate intricate biological pathways with precision. Sethera's polymacrocyclic peptides are designed to interact with complex biological surfaces, providing a novel strategy for addressing diverse therapeutic challenges. The platform supports the creation of various peptide designs, including multiple cross-links and complex intra- and inter-peptide structures, which offer unprecedented control over peptide stability and functionality. Looking ahead, Sethera aims to develop next-generation polymacrocyclic peptides that can engage multiple targets and conjugate various therapeutic payloads, thereby revolutionizing multi-targeted therapies and expanding the horizons of precision medicine.

United States

Sethera is redefining the field of peptide therapeutics with a unique platform that integrates AI, mRNA display, and phage display technologies. We create extensive libraries of constrained peptides, providing unparalleled screening capabilities for drug discovery. Our mission is to accelerate the development of innovative therapies, partnering with industry leaders to bring groundbreaking treatments to market.

Sethera Therapeutics

Company Details